- Home
- OBAI vs LSTA Comparison
OBAI vs LSTA Comparison
Compare OBAI & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OBAI | LSTA |
|---|---|---|
| Founded | 2017 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Misc Health and Biotechnology Services |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.2M | 28.9M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | OBAI | LSTA |
|---|---|---|
| Price | $0.53 | $3.29 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | ★ 1.4M | 90.8K |
| Earning Date | 05-27-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.42 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,283,868.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 56.90 |
| 52 Week Low | $0.44 | $1.81 |
| 52 Week High | $19.95 | $5.07 |
Technical Indicators
Market Signals| Indicator | OBAI | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 21.65 | 35.79 |
| Support Level | $0.44 | $1.91 |
| Resistance Level | $1.66 | $4.95 |
| Average True Range (ATR) | 0.10 | 0.24 |
| MACD | 0.10 | 0.01 |
| Stochastic Oscillator | 18.73 | 50.33 |
Price Performance
Historical ComparisonAbout OBAI TG-17 Inc. Common Stock
Our Bond Inc is a personal security service through its AI-powered Preventive Personal Security platform. It is trusted by corporations, cities, and universities, and has already supported more than 1.4 million security service requests, including over 10,000 emergencies and life-saving interventions.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.